Aurora BioScience | Medical company
Aurora BioScience
Phone: 1300 309 994
Reviews
to load big map
25.01.2022 Endomag’s cancer diagnostic trial underway in US Pivotal trials using Cambridge UK medical technology to fight breast cancer are underway at six sites across the United States. Endomag’s magnetic detection system is under the microscope at the University of California San Francisco and five other sites across the US, including MD Anderson Cancer Center, and will enrol up to 180 breast cancer patients.... The study follows the December approval of Endomag’s Investigational Device Exemption by the United States Food and Drug Administration. The Cambridge company’s Sentimag and Sienna+ magnetic detection system is used during cancer staging in the Sentinel Lymph Node Biopsy (SLNB) procedure and allows surgeons to locate the lymph nodes that potentially harbour cancer with unprecedented sensitivity and accuracy. To use the system, surgeons inject the Sienna+ magnetic tracer into the breast and then use the Sentimag handheld probe to find the sentinel nodes that have taken up the Sienna+. The Endomag system avoids the radioisotopes traditionally used in cancer staging, offers patients a pain-free injection of tracer and gives surgeons more control. Dr Peter Beitsch, of Dallas Surgical, who carried out the first Sentimag procedure in the US, said: This is a breakthrough in sentinel node detection, allowing surgeons to localise nodes precisely and rapidly without any of the concerns associated with the use of radioactivity. This product has the potential to eliminate radioisotopes in sentinel node biopsy, simplifying the procedure for surgeons and making accurate staging more widely available. The system is approved for use in Europe and, since 2012, thousands of cancer patients across 12 European countries have benefited from the new technique. Published results from clinical trials with more than 1,000 breast cancer patients have shown that the Sentimag and Sienna+ system is safe and clinically equivalent to the current gold standard for sentinel lymph node detection. The study aims to provide further clinical evidence that the solution is as safe and effective as the current standard of care with US patients. Endomag’s products also allow the technique to be rolled out to all hospitals and clinics even those without access to radioisotope handling facilities making the procedure more accessible to everyone who needs it. Endomag CEO Eric Mayes believes the US clinical trial will prove transformational to the company’s strategy to have the technology adopted as the worldwide gold standard for cancer patient care. Some of the finest surgeons at cancer centres across the United States are involved in the trial, he added. http://www.businessweekly.co.uk//18083-endomags-cancer-dia
18.01.2022 Dignitana develops a patented scalp cooling system, DigniCap, that reduces chemotherapy-induced hair loss. Dignitana's patented DigniCap system has demonstrated excellent scientific results in clinical studies.
12.01.2022 Depending on the chemotherapy treatment & dose, the DigniCap remains on the scalp post-treatment for btwn 120-150 mins. Once post-infusion cooling is complete,... the cap remains on the head for 15 mins to warm up & reduce any discomfort. #breastcancer #breastcancerawareness #hairlosstreatment #breastcancer #dignicap Breast Cancer Research Centre - WA Aurora BioScience See more
06.01.2022 Hunter Breast Cancer Foundation Partnering with the Master Builders Association and Newcastle Coal Infrastructure Group, the Hunter Breast Cancer Foundation was pleased to be able to donate a second DigniCap scalp cooling system to Newcastle Private Hospital, making it possible to offer up to four four patients simultaneous cooling cap treatment. Newcastle Private Hospital was the first to offer this treatment in the Hunter Region and has been able to treat over 30 patients ...with the cooling cap technology since March. This donor funding was key to installing the second cooling cap system, as the cooling unit costs can be prohibitive to many small hospitals that are keen to embrace this innovative and groundbreaking technology. Cold cap technology is currently only available in a select number of hospitals in Australia and can reduce chemotherapy induced hair loss. The device uses a small refrigerated cooling system to pump a liquid coolant through a cap, which fits snugly around the head. A well-documented side effect of many chemotherapy drugs, hair loss, often significantly impacts the quality of life of many cancer patients. Cooling the scalp during chemotherapy means that less of the chemotherapy drug reaches the follicles and hair is less likely to fall out. Newcastle Private Hospital aims to tailor treatment to meet the needs of individuals and their families, offering access to clinical trials, a McGrath Breast Care Nurse, a Wig Library and the most up to date treatment. http://www.hbcf.org.au//hbcf-partner-to-donate-scalp-cooli
06.01.2022 Heard of the DigniCap? It's a scalp-cooling system donated by us to Breast Cancer Research Centre - WA that is designed to minimise or avoid chemotherapy-induc...ed hair loss among women undergoing chemotherapy treatment for breast cancer. #breastcancer #breastcancerawareness #BCRCWA #hairlosstreatment #dignicap Breast Cancer Research Centre - WA Aurora BioScience See more
02.01.2022 Dignicap fits for patients DIGNICAP FITS FOR PATIENTS CANCER patients are fighting hair loss during chemotherapy and winning thanks to a new piece of equipment on offer at Liverpool’s Sydney Southwest Private Hospital.... The DigniCap scalp cooling system is designed to help limit the amount of hair lost during chemotherapy. Patients wear the cool cap, which makes the small blood vessels around the hair follicles contract and smaller amounts of chemotherapy reach the hair cells resulting in less hairs falling out. Nurse Unit managers Davita Kumar and Julie Cohen have seen three patients benefit already since the new technology arrived in May. http://newslocal.newspaperdirect.com/epaper/viewer.aspx
